Statement of Changes in Beneficial Ownership (4)
May 06 2015 - 5:53PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Chai-Onn Robert Roswell
|
2. Issuer Name
and
Ticker or Trading Symbol
Valeant Pharmaceuticals International, Inc.
[
VRX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
_____ 10% Owner
__
X
__ Officer (give title below)
_____ Other (specify below)
EVP, CLO, General Counsel
|
(Last)
(First)
(Middle)
2150 ST. ELZEAR BLVD. WEST
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/4/2015
|
(Street)
LAVAL, A8 H7L 4A8
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock, no par value
|
5/4/2015
|
|
M
|
|
90938
(1)
|
A
|
$25.42
|
134125
|
D
|
|
Common Stock, no par value
|
5/4/2015
|
|
S
|
|
90938
(1)
|
D
|
$222.5411
(2)
|
43187
|
D
|
|
Common Stock, no par value
|
5/5/2015
|
|
M
|
|
21807
(3)
|
A
|
$6.1
|
64994
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Non-Qualified Stock Options (right to purchase)
|
$25.42
|
5/4/2015
|
|
M
|
|
|
90938
(1)
|
10/8/2014
(4)
|
11/11/2015
|
Common shares, no par value
|
90938
|
$0
|
0
|
D
|
|
Non-Qualified Stock Options (right to purchase)
|
$6.1
|
5/5/2015
|
|
M
|
|
|
21807
(3)
|
11/1/2009
(4)
|
11/1/2015
|
Common shares, no par value
|
21807
|
$0
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
This number represents options exercised and sold pursuant to a 10b5-1 trading plan covering these options, which were to expire on November 11, 2015.
|
(
2)
|
This number represents the weighted average sale price for all sales of common stock acquired upon exercise of options and sold, in each case pursuant to a 10b5-1 trading plan. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price.
|
(
3)
|
This number represents options exercised and held pursuant to a 10b5-1 trading plan covering these options, which were to expire on November 1, 2015.
|
(
4)
|
The options vested one-fourth per year over four years starting with the first vest date falling on the first anniversary of the vesting commencement date, the second vest date falling on the second anniversary of the vesting commencement date, the third vest date falling on the third anniversary of the vesting commencement date, and the fourth vest date falling on the fourth anniversary of the vesting commencement date.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
Chai-Onn Robert Roswell
2150 ST. ELZEAR BLVD. WEST
LAVAL, A8 H7L 4A8
|
|
|
EVP, CLO, General Counsel
|
|
Signatures
|
by: Nicholas Zanoni for Robert Chai-Onn
|
|
5/6/2015
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From Apr 2024 to May 2024
Valeant Pharma (NYSE:VRX)
Historical Stock Chart
From May 2023 to May 2024